TABLE 3.
Frequency and P‐values using crude and adjusted logistic regression model for candidate SNPs (P‐value < 1.E−05)
| Gene name | RS ID | CHR | Physical. position | Genotype | Frequency | Crude model | Adjusted model a | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Control | Case | OR1 (95% CI) | OR2 (95% CI) | P‐value | OR1 (95% CI) | OR2 (95% CI) | P‐value | |||||
| BEND4/SHISA3/ATP8A1 | rs17530621 | 4 | 42 227 497 | G/G | 170 | 18 | 1 | 1 | 3.81.E−06 | 1 | 1 | 3.10.E−06 |
| G/T | 42 | 23 | 4.24 (2.23‐8.06) | 5.15 (2.57‐10.33) | 4.53 (2.33‐8.84) | 5.66 (2.73‐11.72) | ||||||
| T/T | 2 | 1 | 17.97 (4.97‐64.93) | 5.15 (2.57‐10.33) | 20.56 (5.41‐78.09) | 5.66 (2.73‐11.72) | ||||||
| MIR548AB | rs6804462 | 3 | 103 342 570 | G/G | 198 | 27 | 1 | 1 | 3.18.E−06 | 1 | 1 | 4.26.E−06 |
| G/C | 15 | 14 | 5.60 (2.59‐12.11) | 6.87 (3.06‐15.47) | 6.24 (2.86‐13.61) | 7.33 (3.13‐17.16) | ||||||
| C/C | 1 | 1 | 31.35 (6.70‐146.56) | 6.87 (3.06‐15.47) | 38.91 (8.17‐185.28) | 7.33 (3.13‐17.16) | ||||||
| MPP4 | rs11894115 | 2 | 202 512 449 | C/C | 76 | 2 | 1 | 1 | 1.13.E−05 | 1 | 1 | 4.71.E−06 |
| C/T | 102 | 22 | 3.39 (1.97‐5.84) | 10.78 (2.53‐45.92) | 3.96 (2.20‐7.15) | 11.57 (2.69‐49.79) | ||||||
| T/T | 32 | 16 | 11.49 (3.86‐34.16) | 10.78 (2.53‐45.92) | 15.72 (4.83‐51.13) | 11.57 (2.69‐49.79) | ||||||
| RPL7/RDH10 | rs58328254 | 8 | 74 203 722 | G/G | 135 | 12 | 1 | 1 | 1.49.E−05 | 1 | 1 | 6.09.E−06 |
| G/A | 70 | 23 | 3.48 (1.98‐6.11) | 4.29 (2.07‐8.90) | 3.98 (2.19‐7.23) | 4.90 (2.30‐10.47) | ||||||
| A/A | 6 | 6 | 12.09 (3.91‐37.37) | 4.29 (2.07‐8.90) | 15.81 (4.78‐52.28) | 4.90 (2.30‐10.47) | ||||||
| CA10/C17orf112 | rs2113374 | 17 | 50 508 719 | C/C | 186 | 23 | 1 | 1 | 1.38.E−06 | 1 | 1 | 7.06.E−06 |
| C/T | 24 | 18 | 5.29 (2.62‐10.69) | 6.15 (2.94‐12.85) | 5.07 (2.48‐10.36) | 5.73 (2.68‐12.28) | ||||||
| T/T | 1 | 1 | 27.96 (6.85‐114.23) | 6.15 (2.94‐12.85) | 25.71 (6.15‐107.42) | 5.73 (2.68‐12.28) | ||||||
| PRUNE2 | rs117299725 | 9 | 79 423 611 | G/G | 191 | 24 | 1 | 1 | 2.53.E−06 | 1 | 1 | 8.53.E−06 |
| G/A | 24 | 18 | 5.97 (2.84‐12.56) | 5.97 (2.84‐12.56) | 5.69 (2.65‐12.24) | 5.69 (2.65‐12.24) | ||||||
| A/A | 0 | 0 | 35.63 (8.04‐157.79) | 5.97 (2.84‐12.56) | 32.41 (7.01‐149.92) | 5.69 (2.65‐12.24) | ||||||
| CDH13 | rs147631684 | 16 | 83 632 820 | G/G | 202 | 28 | 1 | 1 | 4.50.E−06 | 1 | 1 | 9.61.E−06 |
| G/A | 11 | 13 | 6.21 (2.64‐14.60) | 7.82 (3.25‐18.82) | 6.20 (2.51‐15.34) | 7.97 (3.18‐19.97) | ||||||
| A/A | 1 | 0 | 38.57 (6.98‐213.15) | 7.82 (3.25‐18.82) | 38.50 (6.30‐235.26) | 7.97 (3.18‐19.97) | ||||||
RS ID, reference SNP cluster ID; CHR, chromosome; OR1, odds ratio (OR) and 95% confidence interval (CI) in additive model; OR2, odds ratio (OR) and 95% confidence interval (CI) in dominant model.
a
Adjusted for body mass index and trastuzumab use.